Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System
Pedro Aguiar Jr1, Felipe Roitberg2, Gilberto Lopes Jr3, Auro del Giglio4